Can a simple blood test predict radiation success in rare spine tumors?
NCT ID NCT06463262
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether changes in tumor DNA found in the blood and special imaging scans can predict how well chordoma tumors respond to radiation therapy given before surgery. About 40 adults with chordoma of the spine, skull base, or sacrum will receive proton therapy or stereotactic body radiation therapy. The goal is to see if these markers can replace the current method of checking tumor response after surgery, making treatment monitoring less invasive.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHORDOMA OF SACRUM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johns Hopkins Hospital
RECRUITINGBaltimore, Maryland, 212887, United States
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.